Ketamine for Anxiety: How It Works, What the Research Shows, and What to Expect

Ketamine for anxiety is used off-label as a rapid-acting treatment for generalized anxiety disorder, social anxiety disorder, and anxiety that persists alongside treatment-resistant depression. It is typically given as an intravenous infusion or a sublingual dose under medical supervision. Unlike SSRIs and SNRIs, which can take four to eight weeks to reach full effect, ketamine can reduce anxiety symptoms within hours by acting on the brain's glutamate system rather than serotonin pathways.

According to the World Health Organization, approximately 301 million people worldwide were living with an anxiety disorder as of 2023, making it one of the most common mental health conditions globally. This article explains how ketamine affects anxiety-related brain circuits, what clinical studies have found for specific anxiety diagnoses, and what patients should expect from a course of treatment.

Understanding Anxiety Disorders

Anxiety disorders are among the most common mental health conditions worldwide. The National Institute of Mental Health estimates that roughly 19.1% of U.S. adults experience an anxiety disorder in any given year, and approximately 31.1% will be affected at some point in their lifetime.

The term "anxiety disorder" covers several distinct diagnoses, each with its own symptom pattern:

• Generalized anxiety disorder (GAD): persistent, excessive worry about everyday concerns, often with muscle tension, restlessness, fatigue, and trouble concentrating.
• Social anxiety disorder: intense fear and avoidance of social situations due to worry about being judged or embarrassed.
• Panic disorder: recurrent, unexpected panic attacks with intense physical symptoms and ongoing worry about future attacks.
• Specific phobias: intense, irrational fear of a particular object or situation.
• Agoraphobia: fear and avoidance of situations where escape might be difficult if a panic attack occurs.

These conditions are not simply nervousness or stress. They involve persistent patterns of excessive fear and avoidance that can significantly impair daily functioning, relationships, and quality of life.

Why Current Treatments Fall Short

Standard first-line treatments for anxiety disorders include SSRIs such as sertraline and escitalopram, SNRIs such as venlafaxine and duloxetine, buspirone, benzodiazepines for short-term use, and cognitive behavioral therapy. These approaches help many people, but they have real limitations.

SSRIs and SNRIs typically require four to eight weeks of daily use to reach full effect, which means weeks of continued symptoms for someone in significant distress. An estimated 30% to 40% of patients with anxiety disorders do not achieve adequate relief from conventional medications even after an adequate trial period. See our comparison of ketamine vs. SSRIs for a closer look at how the two approaches differ.

Benzodiazepines act quickly but carry well-documented risks of tolerance, dependence, and withdrawal symptoms with prolonged use. Their sedating effects can also impair daily functioning, and they do not address the underlying neurobiology of anxiety. This treatment gap has driven clinical interest in ketamine as a rapid-acting option for patients whose anxiety has not responded adequately to conventional care.

How Ketamine Affects Anxiety in the Brain

The Glutamate Connection

Glutamate is the brain's primary excitatory neurotransmitter, and research over the past two decades has shown it plays a central role in anxiety. People with anxiety disorders often show altered glutamate signaling in brain regions responsible for threat processing and emotional regulation. Elevated glutamate activity in the amygdala, the brain's threat-detection center, is linked to heightened fear responses, while reduced glutamatergic function in the prefrontal cortex can impair the brain's ability to regulate that fear.

Ketamine's primary mechanismblocking NMDA receptors, engages this glutamate system directly. By modulating glutamate signaling in anxiety-related circuits, ketamine may help restore balance to networks that have become dysregulated.

Neuroplasticity and Anxiety

Chronic anxiety, like chronic depression, appears to weaken synaptic connections in the prefrontal cortex and hippocampus, regions responsible for rational threat evaluation and contextual memory. This may help explain the "stuck" quality of anxiety, the persistent inability to reassess and downregulate exaggerated threat perceptions.

Ketamine promotes rapid synaptogenesis, the formation of new synaptic connections, through its effects on BDNF and the mTOR signaling pathway. By helping rebuild weakened connections in these regulatory regions, ketamine may restore the brain's capacity to process and manage anxiety-provoking stimuli appropriately.

The Fear Extinction Connection

A notable area of research involves ketamine's potential to enhance fear extinction, the process by which the brain learns that a previously threatening stimulus is no longer dangerous. Fear extinction depends on neuroplasticity in the prefrontal cortex and amygdala. Preclinical studies have shown ketamine can facilitate fear extinction learning in animal models. If this translates reliably to humans, it could matter for anxiety disorders involving conditioned fear responses, such as phobias and PTSD.

What the Clinical Research Shows

Generalized Anxiety Disorder

A randomized controlled trial published in 2017 in the Journal of Psychopharmacology evaluated ketamine in patients with GAD and social anxiety disorder. Participants received a single intravenous infusion of ketamine at 0.5 mg/kg over 40 minutes, and the trial found significant reductions in anxiety symptoms, with effects persisting for up to seven days after the single infusion (Glue et al., 2017).

A 2020 systematic review and meta-analysis pooled data from multiple studies on ketamine's anxiolytic properties and found statistically significant reductions in anxiety scores across studies, with effect sizes comparable to those seen in depression trials. A consistent finding across the reviewed research was rapid onset of action, often measurable within hours of administration.

Social Anxiety Disorder

Social anxiety disorder has shown particular responsiveness to ketamine in preliminary research. The glutamate-mediated mechanisms ketamine acts on are especially relevant here, given the role of prefrontal-amygdala circuitry in processing social threat. Clinical observations describe patients reporting reduced anticipatory anxiety before social situations, greater ease during social interactions, less fear of negative evaluation, and improved willingness to approach previously avoided situations. The evidence base for social anxiety specifically is still smaller than for depression, and larger controlled trials are needed before firmer conclusions can be drawn.

Anxiety Co-Occurring With Depression

An estimated 50% to 60% of patients with major depressive disorder also experience significant anxiety symptoms, a presentation sometimes called anxious depression, which is associated with poorer outcomes from conventional treatment. Research on treatment-resistant depression has consistently found that ketamine's antidepressant effects extend to the anxiety component of anxious depression, often with similar magnitude and time course to the depression response.

Panic Disorder

Evidence for ketamine in panic disorder specifically is more limited but encouraging. Case reports and small clinical series describe patients with treatment-resistant panic disorder experiencing reductions in panic attack frequency and severity after ketamine treatment. Rapid onset of action is particularly relevant here, since the unpredictable nature of panic attacks creates its own cycle of anticipatory anxiety.

Treatment Protocols for Anxiety

IV Infusion

The most common protocol for anxiety mirrors the standard depression protocol: 0.5 mg/kg infused intravenously over 40 minutes. An initial series typically involves six infusions over two to three weeks, followed by maintenance infusions at individually determined intervals, commonly every two to six weeks. Some clinicians adjust the dose or infusion rate for anxiety-specific reasons. Patients with high baseline anxiety may benefit from a slower infusion rate or a slightly lower starting dose to minimize anxiety that can occur as dissociative effects begin.

Intranasal Esketamine (Spravato)

Spravato is FDA-approved specifically for treatment-resistant depression, not anxiety disorders, but patients with comorbid anxiety and depression may still receive it. Clinical trial data has shown improvements in anxiety measures among patients treated with Spravato for depression.

Oral and Sublingual Formulations

At-home ketamine treatment using oral or sublingual formulations prescribed through telehealth services is becoming more widely available. These options may suit patients with mild to moderate anxiety who have been carefully evaluated. Oral ketamine has lower bioavailability than IV administration, so effects may be less pronounced, but the accessibility and lower cost make it a reasonable option for ongoing maintenance. For a full comparison of delivery methods, see IV vs. oral vs. nasal ketamine.

What to Expect During and After Treatment

A typical IV ketamine session for anxiety starts with vital sign checks and IV line placement, followed by the infusion itself over about 40 minutes while clinical staff monitor the patient throughout. Dissociative effects, if they occur, tend to peak around 15 to 20 minutes into the infusion. A recovery period of 30 to 60 minutes follows, along with a final vital signs check before discharge. Learn more about what dissociation feels like and how providers manage it in our guide to understanding dissociation.

Many patients report noticeable reductions in anxiety within hours to days of their first session, though individual responses vary. The effects of a single infusion typically last days to weeks, which is why an initial series of multiple sessions matters for building a cumulative response. Between sessions, patients are usually encouraged to continue existing therapies, including psychotherapy and medication, unless their provider recommends changes.

Integration, Cost, and Access

Ketamine therapy for anxiety tends to work best as part of a broader treatment plan rather than a stand-alone fix. Cognitive behavioral therapy in particular may be enhanced by ketamine's neuroplasticity-promoting effects, since the formation of new neural connections could support the learning and behavioral change CBT requires. Some providers combine ketamine sessions directly with therapy; see our overview of ketamine-assisted psychotherapy for how that model works.

Ketamine for anxiety is primarily an off-label use, and insurance coverage is limited. Costs and coverage vary by provider and delivery method, so ask any clinic for a full breakdown before starting treatment. Our provider comparison tool can help you evaluate options side by side.